Startseite Diabetes mellitus with Laron syndrome: case report
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Diabetes mellitus with Laron syndrome: case report

  • Sebahat Yılmaz Agladıoglu EMAIL logo , Semra Cetınkaya , Senay Savas Erdeve , Asan Onder , Havva Nur Peltek Kendırcı , Veysel Nijat Bas und Zehra Aycan
Veröffentlicht/Copyright: 17. Mai 2013

Abstract

There are different opinions concerning changes in glucose metabolism in patients with Laron syndrome. In this paper we discuss the treatment results of our patient with Laron syndrome who developed diabetes during late adolescence. A 19-year-old boy with Laron syndrome was referred to our clinic for follow-up. He had been diagnosed with Laron syndrome (LS) at 4 years old and rIGF-1 therapy was initiated. After 4 months the treatment was discontinued. At the age of 17, rIGF-1 therapy was restarted. A height gain of 8.8 cm. was observed during the 2-year treatment period. He was admitted to our hospital at the age of 19 years following discontinuation of the therapy. At that time, his height was 142 cm, and weight for height was 136%. His blood glucose was 85 mg/dL (4.72 mmol/L), insulin was 26.39 pmol/L, and HbA1c was 5.4%. At the age of 20, when he has not been receiving IGF-1 therapy for 1 year, his weight for height was 143 cm. Laboratory evaluation revealed that fasting blood glucose was 176 mg/dL (9.77 mmol/L), fasting insulin was 29.86 pmol/L, and HbA1c was 7.5%. Primary insulin therapy was then initiated. His parents both had a diagnosis of type 2 diabetes. Insulin therapy was switched to oral antidiabetic (OAD) therapy at the end of the second year because of a normal C-peptide level of 0.8 nmol/L under insulin therapy. After 6 months of OAD, HbA1c was 5.7%. The treatment was then switched to IGF-1 therapy, but his blood glucose profile was impaired and OAD therapy was restarted. In conclusion, we observed that genetic susceptibility and abdominal obesity caused type 2 diabetes in this patient. We believe that oral antidiabetic agents and life-style changes may be the appropriate approach when diabetes is developed in LS patients.


Corresponding author: Sebahat Yılmaz Agladıoglu, MD, Dr. Sami Ulus Training and Research Children’s Hospital, Clinics of Pediatric Endocrinology, Babür Street, 06080, Ankara, Turkey, Phone: +90 312 3056510, Fax: +90 312 3170353, E-mail:

Conflict of interest statement:

The authors declare that they have no conflict of interest, and the study is performed without any financial support.

References

1. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone-a new inborn error of metabolism? Isr JMedSci 1966;2:152–5.Suche in Google Scholar

2. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J MedSci 1968;4:883–94.Suche in Google Scholar

3. Laron Z. Growth hormone resistance (Laron syndrome). In: Chrousos G, editor. Hormone Resistance and Hypersensitivity States. New York: Lippincott Williams & Wilkins, 2002:251–67.Suche in Google Scholar

4. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958–2003. J Clin Endocrinol Metab 2004;89:1031–44.10.1210/jc.2003-031033Suche in Google Scholar

5. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Francke U. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab 1999;84:4436–443.10.1210/jc.84.12.4436Suche in Google Scholar

6. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. GH Insensitivity Syndrome Collaborative Group: Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;3:902–10.10.1210/jc.2006-1610Suche in Google Scholar

7. Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993;68:768–70.10.1136/adc.68.6.768Suche in Google Scholar

8. Laron Z, Klinger B. Body fat in Laron syndrome patients: effects of insulin-like growth factor treatment. Hormone Res 1993;40:16–22.10.1159/000183762Suche in Google Scholar

9. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary GH resistance (Laron syndrome) before and during IGF-I treatment. Metabolism 1995;44(Suppl 4):113–8.10.1016/0026-0495(95)90231-7Suche in Google Scholar

10. Laron Z, Weinberger D. Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur J Endocrinol 2004;151:103–6.10.1530/eje.0.1510103Suche in Google Scholar PubMed

11. Laron Z. Insulin Secretion and Carbohydrate Metabolism in Patients with Laron Syndrome: From Hypoglycemia to Diabetes Mellitus. In: Laron Z, Kopchick J, editors. Laron Syndrome – From Man to Mouse. New York: Springer, 2011:259–272.Suche in Google Scholar

12. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011;3:70ra13.10.1126/scitranslmed.3001845Suche in Google Scholar PubMed PubMed Central

13. Jorge AA, Souza SC, Arnhold IJ, Mendonca BB. Poor reproducibility of IGF-I and IGF binding protein-3 generation test in children with short stature and normal coding region of the GH receptor gene. J Clin Endocrinol Metab. 2002;87:469–72.10.1210/jcem.87.2.8191Suche in Google Scholar PubMed

14. Leslie M. Genetics and disease. Growth defect blocks cancer and diabetes. Science 201;331:837.10.1126/science.331.6019.837Suche in Google Scholar PubMed

15. Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab 2005;16:190–7.10.1016/j.tem.2005.03.011Suche in Google Scholar PubMed

16. Latrech H, Simon A, Beltrand J, Souberbielle JC, Belmejdoub G, et al. Postprandial Hyperglycemia Corrected by IGF-I (Increlex®) in Laron Syndrome. Horm Res Paediatr 2012;78:193–200.10.1159/000339158Suche in Google Scholar PubMed

Received: 2012-12-18
Accepted: 2013-3-24
Published Online: 2013-05-17
Published in Print: 2013-10-01

©2013 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Masthead
  2. Masthead
  3. Review article
  4. Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review
  5. Images in pediatric endocrinology
  6. Solitary median maxillary central incisor, a clinical predictor of hypoplastic anterior pituitary, ectopic neurohypophysis and growth hormone deficiency
  7. A rare case of granuloma annulare in a 6-year-old child with type 1 diabetes
  8. Original articles
  9. The arginine stimulation test: timing of peak is not a helpful parameter in the diagnosis of growth hormone deficiency
  10. The relationship between adiposity and stature in prepubertal children with celiac disease
  11. Influence of micronutrient status and socioeconomic gradient on growth indices of 2–18-year-old Indian girls
  12. Phosphotyrosine phosphatases in GH-stimulated skin fibroblasts from children with idiopathic short stature
  13. The relation between salivary cortisol and the metabolic syndrome score in girls
  14. Association of vitamin D concentrations with adiposity indices among preadolescent children in Korea
  15. Association of serum resistin levels with metabolic syndrome and early atherosclerosis in obese Chinese children
  16. Characteristics of infants at risk of hypoglycaemia secondary to being ‘infant of a diabetic mother’
  17. Parental dyadic coping in families of children and adolescents with type 1 diabetes
  18. Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome is associated with severe chronic inflammation and cardiomyopathy, and represents a new monogenic autoinflammatory syndrome
  19. Effect of insulin therapy on IGF-1 level in children with new-onset type 1 diabetes mellitus: a comparison between DKA and non-DKA
  20. Mutation analysis of the SRD5A2, AR and SF-1 genes in 52 Chinese boys with hypospadias
  21. Sexual development in prepubertal obese boys: a 4-year longitudinal study
  22. Genetic diagnosis of one family with incomplete clinical data
  23. Patient reports
  24. Complete androgen insensitivity syndrome and discordant Müllerian remnants: two cases with novel mutation in the androgen receptor
  25. Psychosexual outcomes in three siblings with partial androgen insensitivity syndrome: impact of nature versus nurture
  26. Ambiguous genitalia in a 48, XXYY newborn: a casual relationship or a coincidence?
  27. Gonadal function of beta-thalassemics following stem cell transplantation conditioned with myeloablative and reduced intensity regimens
  28. Significant testicular enlargement in a 6.5-year-old boy with monorchism and testicular microlithiasis
  29. Report of the first case of precocious puberty in Rett syndrome
  30. Type II vitamin D-dependent rickets with diabetic ketoacidosis
  31. Pituitary gigantism presenting with depressive mood disorder and diabetic ketoacidosis in an Asian adolescent
  32. A rare association between Rathke’s cyst and hypophysitis in a patient with delayed sex development and growth failure
  33. Diabetes mellitus with Laron syndrome: case report
  34. Wegener granulomatosis as an uncommon cause of panhypopituitarism in childhood
  35. Rare cases of autoimmune hypothyroidism in young children
  36. Cushing syndrome related to leukemic infiltration of the central nervous system: a case report and a possible role of LIF
  37. Early presentation of bilateral gonadoblastomas in a Denys-Drash syndrome patient: a cautionary tale for prophylactic gonadectomy
  38. Identification of a novel homozygous mutation (S144I) in a Malay patient with maple syrup urine disease
  39. Virilization in two pre-pubertal children exposed to topical androgen
  40. A family with Camurati-Engelman disease. The role of the missense p.R218C mutation in TGFB1 in bones and endocrine glands
  41. Short communications
  42. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes
  43. Assessment of contractility and myocardial function in small and appropriate for gestational age premature neonates using the stress-velocity relationship and tissue Doppler imaging immediately after birth
  44. Letter to the Editors
  45. Homeostasis model assessment of insulin resistance may not be reliable to evaluate insulin sensitivity in young obese children
  46. Type 1 diabetes in women with endometriosis: what is the risk of occurrence?
  47. How should we manage vitamin D-deficient adolescents?
  48. Should neonatal hyperparathyroidism associated with mucolipidosis II/III be treated pharmacologically?a
Heruntergeladen am 8.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2012-0411/pdf
Button zum nach oben scrollen